PSMA PET/CT appears highly likely to identify and stage prostate cancer in patients at least 80 years old with a PSA level of at least 20 ng/mL, even without biopsy confirmation, according to investigators.
Features
The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
This report reviews the challenges patients with bladder cancer experience related to cystectomy and urinary diversion surgery.
A review of the benefits of exercise for men with prostate cancer describes exercises and routines that may improve outcomes for this patient population.
Investigators reported findings from the first randomized trial to evaluate the use of metastasis-directed therapy with hormone therapy in patients with oligometastatic prostate cancer.
Each 10% increase in PSA screening rates was significantly associated with a 9% decrease in the metastatic prostate cancer rates, according to a study of VA medical centers.
Final results from the TITAN-RCC trial demonstrate improvements in objective response rates compared with nivolumab monotherapy.
PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.